COMING SOON - Massive Insider Buying and HERE'S WHY.

[mnholdem]

It seems to me that it's a major conflict of interest that MannKind's Investor Relations are handled by the CFO, the one person who clearly understands the tax ramifications.

I would never intentionally imply that Matt is working to drive down share prices. But he sure as hell doesn't appear to be worried about it either.

Hopefully they start buying when the HSR is returned approving the Sanofi license agreement.

[mannmade]

Sept 13, 2014 22:27:31 GMT -5 mnholdem said:

It seems to me that it's a major conflict of interest that MannKind's Investor Relations are handled by the CFO, the one person who clearly understands the tax ramifications.

I would never intentionally imply that Matt is working to drive down share prices. But he sure as hell doesn't appear to be worried about it either.

Hopefully they start buying when the HSR is returned approving the Sanofi license agreement.

I am not suggesting this by any means.. Rather I was suggesting that SNY would be smart to be taking advantage of the effect of a low pps that has occurred from the huge short volume which I do not believe is related to any action on the part of mnkd but yet serves to benefit a smart investment team at Sanofi... And in the end if true then will also benefit us as the shareholders, as I believe it would be the catalyst for a dramatic short squeeze... And in the meantime is a gift to those who can afford to accumulate more..

And btw I believe Matt to be totally above board and very concerned about ethics from everything I have heard him say...  His responses to questions have always been honest even when he does not have the answer or cannot say for legal reasons he will at least let us know that... Let me be clear about my belief on this subject... This company has done nothing in my mind to even hint or suggest they would be a part of this intentionally... I am just saying that with every investment scenario and cycle such as with real estate for example, (which I have investment experience in) there are ways to make it work as an investor.  Similarly when real estate is depressed it is a great time to buy and hold until it rises again...

I do agree that up until now, share price may not have been their number one priority, however, in my opinion the number one priority was (and rightly so) getting Afrezza approved by the FDA and then finding the right partner.  They have made attempts to manage some of the PR issues such as when they put up the FAQ section on their site (which by the way they now update and keep current) but honestly they are a start up with a lot more critical issues to worry about... And not with a huge admin staff I might add, hence the "double duty."  They run very lean and Matt is very knowledgeable about the science as well as the finances of the company.

But now that they have delivered on their end it seems to me that it is SNY's job when it comes to the PR regarding Afrezza and we know they are not too keen at this point on revealing much for competitive reasons.

And by the way I/we don't know the level of concern they have or do not have for pps issues.  However, no one has more at risk then Al.  And to tell you the truth I think they are just as surprised as the rest of us as they have said so before...  This stock has a very different story than most that I have seen and it revolves around mystifying pps that consistently seems to drop with good news.  However, the parties responsible for this, in my opinion, are the Karps, Cramers and Feursteins of the world not the Mannkind staff... Let's face it they suffer as much as we do and have no real incentive...  It is seemingly out of everyone's control except the shorts...

Also, honestly even with all the good news... you could make a case that mnkd is very fairly valued at 2.5B to 3B with no revenues which is the current pps.  What will begin to drive the pps higher are the catalysts that allow us to begin to factor in forward earnings based on projections that will for now have to come from analysts... So this is a very speculative stock on both sides and so far it is the shorts who are winning...  Mnkd has been called a "Battleground Stock" And the shorts have been seeming to win most of the battles... But they are only winning battles as the longs will win the war...

I will also tell you from personal experience that yes it is tough but sometimes the better strategy is to remain quiet while you execute your plan.  The last thing they need to do is to be seen as reactionary which could imply a certain amount of defensiveness that would ad more fuel to the fire for shorts...  They have made a choice about how to respond which has been to stay the course... and in the course of doing so they have delivered the FDA approval and partner... And now are working on Danbury with production to start in November and support of Sales launch with SNY in 1st Q 2015... So all I am saying (yes a long answer) is they see grinding it out and just following through as the best long term solution and at this point I think perhaps they are right...